Advertisement

Apremilast: A Review in Oral Ulcers of Behçet’s Disease

  • 26 Accesses

Abstract

The oral phosphodiesterase 4 inhibitor apremilast (Otezla®) is indicated for the treatment of oral ulcers associated with Behçet’s disease in some countries, including the USA (where it is the first agent approved for the disease) and Japan. In phase 2 and 3 trials in adults with this chronic and debilitating disorder, 12 weeks of treatment with apremilast 30 mg twice daily reduced the number and pain of oral ulcers and disease activity relative to placebo, with these clinical benefits being accompanied by improvements in health-related quality of life (HR-QOL). Benefits of apremilast were seen regardless of baseline patient/disease characteristics and in Japanese patients, and were sustained over up to 64 weeks of treatment. Apremilast was generally well tolerated, with gastrointestinal adverse events being among the most common tolerability issues. Emerging real-world data also support the drug’s use in this setting. Thus, for patients with oral ulcers associated with Behçet’s disease, apremilast provides an effective and generally well tolerated approved treatment option.

This is a preview of subscription content, log in to check access.

Access options

Buy single article

Instant unlimited access to the full article PDF.

US$ 49.95

Price includes VAT for USA

Fig. 1

References

  1. 1.

    Mayo Clinic. Behcet’s disease. 2019. https://www.mayoclinic.org. Accessed 6 Dec 2019.

  2. 2.

    Tong BN, Liu XL, Xiao J, et al. Immunopathogenesis of Behcet’s disease. Front Immunol. 2019;10:665. https://doi.org/10.3389/fimmu.2019.00665.

  3. 3.

    Hatemi G, Yazici Y, Yazici H. Behcet’s syndrome. Rheum Dis Clin N Am. 2013;39(2):245–61.

  4. 4.

    Hatemi G, Christensen R, Bang D, et al. 2018 update of the EULAR recommendations for the management of Behcet’s syndrome. Ann Rheum Dis. 2018;77(6):808–18.

  5. 5.

    Nair JR, Moots RJ. Behcet’s disease. Clin Med. 2017;17(1):71–7.

  6. 6.

    Adeeb F, Stack AG, Fraser AD. Knitting the threads of silk through time: Behcet’s disease—past, present, and future. Int J Rheumatol. 2017;2017:2160610. https://doi.org/10.1155/2017/2160610.

  7. 7.

    Schafer PH, Parton A, Gandhi AK, et al. Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis. Br J Pharmacol. 2010;159(4):842–55.

  8. 8.

    Celgene Corporation. Otezla® (apremilast) tablets, for oral use: US prescribing information. 2019. https://dailymed.nlm.nih.gov/. Accessed 6 Dec 2019.

  9. 9.

    Celgene Co., Ltd. Otezla® tablets: Japanese prescribing information. Tokyo: Celgene co., Ltd; 2019.

  10. 10.

    Schafer PH, Parton A, Capone L, et al. Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunity. Cell Signal. 2014;26(9):2016–29.

  11. 11.

    Perez-Aso M, Montesinos MC, Mediero A, et al. Apremilast, a novel phosphodiesterase 4 (PDE4) inhibitor, regulates inflammation through multiple cAMP downstream effectors. Arthritis Res Ther. 2015;17:249.

  12. 12.

    Schafer P. Apremilast mechanism of action and application to psoriasis and psoriatic arthritis. Biochem Pharmacol. 2012;83(12):1583–90.

  13. 13.

    Schafer PH, Truzzi F, Parton A, et al. Phosphodiesterase 4 in inflammatory diseases: effects of apremilast in psoriatic blood and in dermal myofibroblasts through the PDE4/CD271 complex. Cell Signal. 2016;28(7):753–63.

  14. 14.

    McCann FE, Palfreeman AC, Andrews M, et al. Apremilast, a novel PDE4 inhibitor, inhibits spontaneous production of tumour necrosis factor-alpha from human rheumatoid synovial cells and ameliorates experimental arthritis. Arthritis Res Ther. 2010;12(3):R107.

  15. 15.

    Mizuki N, Meguro A, Ota M, et al. Genome-wide association studies identify IL23R-IL12RB2 and IL10 as Behcet’s disease susceptibility loci. Nat Genet. 2010;42(8):703–6.

  16. 16.

    Remmers EF, Cosan F, Kirino Y, et al. Genome-wide association study identifies variants in the MHC class I, IL10, and IL23R-IL12RB2 regions associated with Behcet’s disease. Nat Genet. 2010;42(8):698–702.

  17. 17.

    Maranville J, Medvedeva I, Yang R, et al. Pharmacogenetics and pharmacodynamics of response to apremilast in a phase 3 clinical study in subjects with active Behcet’s disease [abstract/poster no. 1694]. In: American College of Rheumatology and Association for Rheumatology Health Professionals annual meeting; 2019.

  18. 18.

    Palmisano M, Wu A, Assaf M, et al. The effects of apremilast on the QTc interval in healthy male volunteers: a formal, thorough QT study. Int J Clin Pharmacol Ther. 2016;54(8):613–21.

  19. 19.

    Hatemi G, Melikoglu M, Tunc R, et al. Apremilast for Behcet’s syndrome—a phase 2, placebo-controlled study. N Engl J Med. 2015;372(16):1510–8.

  20. 20.

    Hatemi G, Mahr A, Ishigatsubo Y, et al. Trial of apremilast for oral ulcers in Behçet’s syndrome. N Engl J Med. 2019;381(20):1918–28.

  21. 21.

    Atienza-Mateo B, Martin-Varillas JL, Loricera J, et al. Apremilast in refractory oral and/or genital ulcers in Behcet’s disease. Multicenter study of 49 cases in clinical practice [abstract no. SAT0215]. Ann Rheum Dis. 2019;78(Suppl 2):1182–3.

  22. 22.

    Lopalco G, Venerito V, Leccese P, et al. Real-world effectiveness of apremilast in multirefractory mucosal involvement of Behcet’s disease [letter]. Ann Rheum Dis. 2019. https://doi.org/10.1136/annrheumdis-2019-215437.

  23. 23.

    De Luca G, Cariddi A, Campochiaro C, et al. Efficacy and safety of apremilast for Behcet’s syndrome: a real-life single-centre Italian experience. Rheumatology. 2019. https://doi.org/10.1093/rheumatology/kez267.

  24. 24.

    Hatemi G, Mahr A, Takeno M, et al. Improvements in disease activity and quality of life for up to 64 weeks in patients with Behcet’s syndrome: results from the RELIEF study [poster no. OP03.04]. In: 28th European Academy of Dermatology and Venereology congress; 2019.

  25. 25.

    Dobashi H, Tanaka Y, Kono H, et al. Efficacy of apremilast for oral ulcers associated with active Behçet’s syndrome over 28 weeks in a Japanese subgroup: results from a phase III study [poster no. W-72-6]. In: 63rd annual general assembly and scientific meeting of the Japan College of Rheumatology; 2019.

  26. 26.

    Hatemi G, Mahr A, Takeno M, et al. Improvements and correlations in oral ulcers, disease activity, and quality of life in Behcet’s syndrome patients treated with apremilast: a phase III randomized, double-blind, placebo-controlled study (RELIEF) [abstract no. 9892]. J Am Acad Dermatol. 2019;81(4 Suppl 1):AB78.

  27. 27.

    Hatemi G, Mahr A, Takeno M, et al. Efficacy of apremilast for oral ulcers associated with active Behcet’s syndrome over 64 weeks: results from a phase III study [abstract no. OP0146 plus oral presentation]. Ann Rheum Dis. 2019;78(Suppl 2):148–9.

  28. 28.

    Takeno M, Tanaka Y, Kono H, et al. Efficacy of apremilast for oral ulcers associated with active Behcet’s syndrome over 64 weeks: long-term results from the Japanese subgroup in a phase III study [abstract and poster no. 1697]. In: American College of Rheumatology and Association for Rheumatology Professionals annual meeting; 2019.

  29. 29.

    Hatemi G, Mahr A, Takeno M, et al. Improvements in disease activity and quality of life for up to 64 weeks in patients with Behçet’s syndrome: results from the RELIEF study [oral presentation 0946]. In: American College of Rheumatology/Association of Rheumatology Health Professionals annual meeting; 2019.

  30. 30.

    Kono H, Dobashi H, Tanaka Y, et al. Apremilast for Behcet’s syndrome: results from a phase III, randomized, double-blind, placebo-controlled study in a Japanese subgroup [poster no. 13]. In: 18th international conference on Behcet’s disease; 2018.

  31. 31.

    Alpsoy E. New evidence-based treatment approach in Behcet’s disease. Pathol Res Int. 2012;2012:871019. https://doi.org/10.1155/2012/871019.

  32. 32.

    Leccese P, Ozguler Y, Christensen R, et al. Management of skin, mucosa and joint involvement of Behcet’s syndrome: a systematic review for update of the EULAR recommendations for the management of Behcet’s syndrome. Semin Arthritis Rheum. 2019;48(4):752–62.

Download references

Acknowledgements

During the peer review process, the marketing authorization holder of apremilast was also offered the opportunity to review this article. Changes resulting from comments received were made on the basis of scientific and editorial merit.

Author information

Correspondence to Emma D. Deeks.

Ethics declarations

Funding

The preparation of this review was not supported by any external funding.

Conflict of interest

Emma Deeks is a salaried employee of Adis International Ltd/Springer Nature, is responsible for the article content and declares no relevant conflicts of interest.

Additional information

Enhanced material for this Adis Drug Evaluation can be found at https://doi.org/10.6084/m9.figshare.11435352.

The manuscript was reviewed by: V. Hamuryudan, Division of Rheumatology, Department of Internal Medicine, Cerrahpasa Medical School, University of Istanbul-Cerrahpasa, Istanbul, Turkey; Y. Kirino, Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine, Yokohama, Japan.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Deeks, E.D. Apremilast: A Review in Oral Ulcers of Behçet’s Disease. Drugs (2020) doi:10.1007/s40265-019-01253-3

Download citation